Vaishali Pharma Ltd
Incorporated in 1989, Vaishali Pharma Ltd
does marketing of pharmaceutical products including active pharmaceutical ingredients[1]
- Market Cap ₹ 90.3 Cr.
- Current Price ₹ 6.92
- High / Low ₹ 13.6 / 4.75
- Stock P/E
- Book Value ₹ 5.16
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 2.00
Pros
Cons
- Promoter holding is low: 31.6%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 11% |
| 3 Years: | -21% |
| 1 Year: | -44% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2017 | Mar 2019 | Aug 2020 | Feb 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Number of Countries Presence Number |
|
||||
| Number of Approved Product Registrations Number |
|||||
| Number of Customers Number |
|||||
| Number of Employees Number |
|||||
| Number of Registered Brands Number |
|||||
| Number of Brands in Pipeline Number |
|||||
| Number of Manufacturing Sites (Third Party) Number |
|||||
| Pending Order Book INR Crores |
|||||
| Pending Order Book (Formulations/Export) INR Crores |
|||||
| Total Number of Products Number |
|||||
Extracted by Screener AI
Documents
Announcements
-
Price movement
22 April 2026 - Vaishali Pharma says price movement is market-driven, with no undisclosed material information.
-
Price movement
21 April 2026 - Investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written …
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
11 April 2026 - Submitted Regulation 74(5) compliance certificate for quarter ended 31 March 2026.
-
Disclosure under SEBI Takeover Regulations
10 April 2026 - Promoter group confirms no encumbrance on Vaishali Pharma shares during FY ended 31 March 2026.
-
General Updates
2 April 2026 - Promoter disclosed no encumbrance on Vaishali Pharma shares for FY ended 31 March 2026.
Annual reports
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2020TranscriptAI SummaryPPT
-
May 2020TranscriptAI SummaryPPT
Business Overview:[1]
VPL is certified by ISO 9001:2008 and provides 1500+ products and 250+ Brands including APIs, Formulations, Surgical, Herbals, Veterinary, Nutraceutical, Oncology, and other healthcare products in 35+ locations